ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Zydus receives Orphan Drug Designation from US FDA for malaria treatment
December 17, 2021The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US. -
Zydus announces completion of Phase-I trials of ZY19489
February 05, 2021Zydus Cadila announced that its anti-malarial compound ZY19489 (MMV253) in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has now completed Phase I clinical evaluation [Reg’n Number ACTRN12619000127101].
Pharma Sources Insight January 2025
